Steps in the Right Direction - Featured Research on Poniard Pharmaceuticals, Inc. and Gilead Sciences, Inc.

   Today, www.BollingerReport.com introduced featured coverage of Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) and Gilead Sciences, Inc. (NASDAQ: GILD). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=PARD&sm2=GILD.

With the European Financial Stability Facility set to increase to $1.4 trillion, it marks a significant move forward to strengthen the safety net in place for Europe's most troubled countries. Private bondholders of Greek debt are settling at a 50% haircut as another $180 billion in fresh aid is set to arrive, enabling banks to recapitalize at a healthy 9% reserve. Overall, these measures will bring Greece's debt burden down to 120% of GDP by 2020. An important consideration is political commitment to this road map. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.

Bollinger Report screened and selected Poniard Pharmaceuticals, Inc. for its current position within the healthcare industry. Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapeutics. The Company's lead product candidate is picoplatin, a new generation platinum-based cancer therapy. A copy of this report featuring Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) is available at: www.BollingerReport.com/index.php?sm1=PARD.

Bollinger Report is featuring Gilead Sciences, Inc. for its changing role within the healthcare industry. Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company. The Company focuses on the development and commercialization of human therapeutics for life threatening diseases. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Truvada, Atripla, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and Cayston. To download researches and analysis on Gilead Sciences, Inc. (NASDAQ: GILD) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=GILD.

About Bollinger Report Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.

Contact: Martin Schwartz Email Contact www.BollingerReport.com